» Articles » PMID: 14594443

Pharmacological Management of Neuropathic Pain

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2003 Nov 5
PMID 14594443
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In health, the nervous system exists in a balance between inhibitory and excitatory influences. This balance may be upset if neural tissue is damaged or irritated and may give rise to neuropathic pain. Such neuropathic pain does not respond consistently to opioid analgesics or NSAIDs and it may therefore be necessary to utilise other therapeutic agents with known activity on either the excitatory or inhibitory components of the pain pathway. These other agents are traditionally considered with reference to their original uses; we still refer to tricyclic antidepressants (TCAs) and anticonvulsant drugs when a consideration of their modes of action may allow more rational use. For example, carbamazepine is related to the TCAs by virtue of its chemical structure and proposed mode of action and yet is still classified as an anticonvulsant drug. With respect to the opioids, increasing evidence points to an analgesic effect in neuropathic pain, although concerns regarding tolerance and dependence still prevent more widespread use. The anticonvulsants comprise a group of compounds possessing anticonvulsant and analgesic properties, but each possesses differing modes of action and so several members of the class should be tried before a conclusion is reached that they, as a whole, are ineffective. TCAs may also have a role in the treatment of neuropathic pain. As with all drugs, if their use is not associated with pain relief in a defined period of time, their use should be terminated. Topical TCAs may also have a role where the area of neuropathic pain is small. Other options, such as SSRIs, membrane stabilisers, capsaicin, baclofen and clonidine may have potential in treating neuropathic pain. The available evidence regarding the efficacy of currently available agents for the treatment of neuropathic pain is sparse. With the knowledge of achieving analgesia, according to the modes of actions of various agents it is hoped that the treatment of this difficult condition may be more logical and successful.

Citing Articles

Amitriptyline nanoparticle repositioning prolongs the anti-allodynic effect of enhanced microglia targeting.

Kim S, Yang J, Shin J, Shin N, Shin H, Lee J Nanomedicine (Lond). 2024; 19(25):2099-2112.

PMID: 39229790 PMC: 11485917. DOI: 10.1080/17435889.2024.2390349.


2024 ISFM and AAFP consensus guidelines on the long-term use of NSAIDs in cats.

Taylor S, Gruen M, KuKanich K, Lascelles B, Monteiro B, Sampietro L J Feline Med Surg. 2024; 26(4):1098612X241241951.

PMID: 38587872 PMC: 11103309. DOI: 10.1177/1098612X241241951.


Drosophila pain sensitization and modulation unveiled by a novel pain model and analgesic drugs.

Jang W, Oh M, Cho E, Baek M, Kim C PLoS One. 2023; 18(2):e0281874.

PMID: 36795675 PMC: 9934396. DOI: 10.1371/journal.pone.0281874.


Pre-Clinical Assessment of the Nose-to-Brain Delivery of Zonisamide After Intranasal Administration.

Goncalves J, Alves G, Carona A, Bicker J, Vitorino C, Falcao A Pharm Res. 2020; 37(4):74.

PMID: 32215749 DOI: 10.1007/s11095-020-02786-z.


Diclofenac Inhibits 27-hydroxycholesterol-induced Differentiation of Monocytic Cells into Mature Dendritic Cells.

Son Y, Kim B, Park Y, Kim K Immune Netw. 2017; 17(3):179-185.

PMID: 28680379 PMC: 5484648. DOI: 10.4110/in.2017.17.3.179.


References
1.
Heughan C, Allen G, Chase T, Sawynok J . Peripheral amitriptyline suppresses formalin-induced Fos expression in the rat spinal cord. Anesth Analg. 2002; 94(2):427-31, table of contents. DOI: 10.1097/00000539-200202000-00038. View

2.
Max M, Lynch S, Muir J, Shoaf S, Smoller B, Dubner R . Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992; 326(19):1250-6. DOI: 10.1056/NEJM199205073261904. View

3.
Gilron I, Booher S, Rowan J, Max M . Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol. 2001; 24(2):109-12. DOI: 10.1097/00002826-200103000-00009. View

4.
Ansuategui M, Naharro L, Feria M . Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats. Psychopharmacology (Berl). 1989; 98(1):93-6. DOI: 10.1007/BF00442012. View

5.
Lees G, Leach M . Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res. 1993; 612(1-2):190-9. DOI: 10.1016/0006-8993(93)91660-k. View